Neuroone Medical Technologies Corporation · NASDAQ:NMTC
Neuroone Medical Technologies — Investor Presentation (August 2026)
21 slides from Neuroone Medical Technologies's investor presentation, August 2026
Slide 1: Corporate Presentation
ADVANCING NEUROSCIENCE Corporate Presentation Brain & Pain Electrode Platform Nasdaq: NMTC August 2026
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Except for statements of historical fact, any information contained in thi
Slide 3: Our Vision
Our Vision Clara, 18 years old We are Driven to Transform 10 the Lives of Patients Battling seizures nightly Neurological Disease and Chronic Pain — Conditions That Have Long Deserved to seizure Better Solutions free for 1 year* * Disclaimer: This recounts a patient's experience and may not be repre
Slide 4: Investment Highlights
Investment Highlights Validated Platform • 4 FDA 510(k) Clearances Technology • Partnership with • Underpenetrated epilepsy and trigeminal neuralgia ablation Underpenetrated opportunity Enabled by Core Markets • $200m+ market with significant Proprietary growth potential Flexible Thin Film Electrode
Slide 5: Competitive Moat Around Every Product We Build
Competitive Moat Around Every Product We Build Proprietary Flexible Thin Film Platform Technology Combined Diagnostic and Ultra-Thin / Therapeutic Capabilities Flexible • Only FDA-Cleared device that uses the • Significantly less invasive same sEEG electrode for both • Enables percutaneous (needle)
Slide 6: Our Platform Addresses Multi-billion $ and Growing Markets
Our Platform Addresses Multi-billion $ and Growing Markets¹ $1B+ $1B+ $1B+ $10B+ $200M $25M $3B $200M $3B Epilepsy and Trigeminal Drug BVNA Spinal Cord Stimulation Neuralgia2 Delivery (Back Pain) (Back Pain) Actual Market Potential Market Size 1. Company data on file 2. Brain EEG and RF ablation for
Slide 7: Mayo Clinic Partnership
Mayo Clinic Partnership • Mayo Clinic performed initial testing of technology in pre-clinical models and clinical research • Mayo Clinic leading neurologist, Dr. Worrell, chairs the NeuroOne Scientific Advisory Board • First commercial human use of Evo® Cortical Electrodes performed at Mayo Clinic i
Slide 8: Zimmer Biomet Partnership
Zimmer Biomet Partnership • Zimmer - worldwide leader in robotic technology used in minimally invasive neurosurgeries • NeuroOne sEEG electrodes are complementary to Zimmer’s ROSA ONE® robotic neurosurgery platform • Partnership initiated in 2020: $8.5 million total licensing revenue paid to NeuroOn
Slide 9: Technology Platform
Technology Platform 9 NASDAQ: NMTC
Slide 10: Product Portfolio
Product Portfolio Product Use Case Partner FDA Cleared Recording brain activity Evo® Cortical Electrodes placed on surface of brain 510(k) Recording brain activity Evo® sEEG Electrodes Placed deeper Into the brain 510(k) Brain OneRF® Ablation System Ablating brain tissue using sEEGs 510(k) for Brain
Slide 11: Thin-Film Evo sEEG & Cortical Electrodes
Neurology 510(K) Cleared Thin-Film Evo® sEEG & Cortical Electrodes Evo® Cortical Summary • Increased signal clarity /reduced noise design • Cortical device thinner & lighter than competitive devices • sEEG - Better tactile feedback during brain tissue insertion • Both product lines are distributed b
Slide 12: OneRF Ablation System for Brain
Neurology 510(K) Cleared OneRF® Ablation System for Brain Summary Evo® sEEG • One procedure for diagnostic and therapeutic expected to save time, money and to improve patient outcomes • Temperature-guided ablation provides additional safety measure Single-Use RF Procedure • Designed to reduce number
Slide 13: OneRF Trigeminal Nerve Ablation System for Facial Pain
Chronic Pain 510(K) Cleared OneRF® Trigeminal Nerve Ablation System for Facial Pain (Trigeminal Neuralgia-TN) Received 510(k) clearance from FDA in August 2025 Summary Single Use: TNRF Probe & Cannula • Treatment with proven clinical efficacy with established reimbursement • OneRF introduces the fir
Slide 14: BVNA – Leveraging Existing NeuroOne Technologies
Chronic Pain In Development BVNA – Leveraging Existing NeuroOne Technologies Key Highlights of the System Multi-contact probe Next-Gen Multi-Contact Probe • More contacts = more placement flexibility (FDA cleared for brain and • Temperature controlled ablation trigeminal nerve ablation) • Gen 2 – De
Slide 15: StereoCED Drug Delivery System
Neurology In Development StereoCED Drug Delivery System Designed to leverage our sEEG platform enabling drug delivery + brain activity recording Pre-Drug Delivery Drug Delivery Post-Drug Delivery Drug Delivery Time Lapse Record Brain Activity Via Catheter Inserted Record Brain Activity with Illustra
Slide 16: Spinal Cord Percutaneous Paddle Lead
Chronic Pain In Development Spinal Cord Percutaneous Paddle Lead Summary Perc-Paddle Lead (Electrode) • Percutaneously placed paddle electrodes through a 14- gauge needle for spinal cord stimulation • Able to stimulate broadly and precisely target tissue; ability to customize different stimulation p
Slide 17: Management Team
Management Team Dave Rosa Chris Volker, CFA David Wambeke President & Chief Chief Financial Chief Business Executive Officer Officer Officer Steve Mertens Evan Goulet Emily Johns Chief Technology Sr. Director of QA and RA Chief Administrative Officer Officer & General Counsel Mark Christianson Hijaz
Slide 18: Financial Overview
Financial Overview Capital Position (as of 6/30/26) Highlights & Financial Catalysts ($ in millions) • Debt free balance sheet Cash $2.0 • Backlog through fiscal Q3 - $1.7M Accounts Receivable $1.1 • Q3 FY2026 Financials: – Product revenue of $2.0M Debt $0.0 – Product gross margin of 59.9% • FY26 pr
Slide 19: Potential Near-Term Catalysts
Potential Near-Term Catalysts • Release of StereoCED Drug Delivery System for animal research and approved IDE studies • Full launch of OneRF Trigeminal Neuralgia Ablation System • Strategic Partnerships for pain applications • OneRF Brain Ablation Registry Data • International Expansion of the OneR
Slide 20: Key Takeaways
Key Takeaways Validated platform Underpenetrated technology $200+ million neurology market with significant growth opportunity $3+ billion market Driving revenue expansion opportunity growth, improving financial profile, and strategic collaboration potential 20 NASDAQ: NMTC
Slide 21: Thank You
Thank You Investor Relations: Chris Tyson Executive Vice President MZ North America Direct: 949-491-8235 NMTC@mzgroup.us 21 NASDAQ: NMTC
NeuroOne Medical Technologies — Investor Presentation (August 2026) on 6ix